Evidence map›Paper›PMID 39466561›Full record

ArticleJournal of neuro-oncology2025

Pituitary neuroendocrine tumors treated with stereotactic radiosurgery.

Inhwa Kim, Michael Yan, Michel Sourour, Robert Heaton, Colin Faulkner, Aristotelis Kalyvas, Dana M Keilty, Michael D Cusimano, David Payne, Normand Laperriere and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Inhwa KimDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Michael YanRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Michel SourourDivision of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
Robert HeatonRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Colin FaulknerDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Aristotelis KalyvasDivision of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
Dana M KeiltyRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Michael D CusimanoDivision of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
David PayneRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Normand LaperriereRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
David B ShultzRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Saira B AlliDivision of Neurosurgery, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Gelareh ZadehDivision of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. derek.tsang@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePituitary neuroendocrine tumors (pitNETs) are benign tumors that may recur after surgical resection or persist following medical management. The objective of this study was to evaluate outcomes and toxicities of patients with pitNETs treated with stereotactic radiosurgery (SRS) at a single institution.

methodsWe completed a retrospective, single-institution study of patients with pitNETs treated with frame-based, single-fraction, cobalt-60 SRS between September 2005 and June 2023. The primary endpoint was local tumor control. Secondary endpoints included endocrine control (for functional tumors), overall survival, and toxicities.

resultsA total of 88 lesions in 83 patients were treated with SRS. Most lesions (70%) were non-functional tumors. Of the 26 functioning tumors, 6 patients achieved endocrine remission with SRS alone (23%), and the remainder achieved remission with combined medical management. With a median patient follow-up of 4.7 years, no local tumor recurrences were observed with an estimated local control probability of 100%. Two- and five-year overall survival estimates were 97% (95% confidence interval [CI] 89-99) and 95% (95% CI 84-98), respectively. Causes of death were unrelated to PitNET or SRS. Twelve patients (14%) developed hypopituitarism after SRS. Despite the 34 lesions that were ≤ 3 mm from optic structures, no patients developed any optic neuropathy or visual decline post SRS.

conclusionsSRS is a highly effective modality for recurrent or residual pitNETs. This study observed a local control of 100% with no cases of optic toxicities after a median follow-up of 4.7 years. These observed findings suggest that dose de-escalation may be possible for future treatment of pitNETs.

Indexed as

Neuroendocrine TumorsPituitary NeoplasmsRadiosurgeryAdolescentAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultRadiosurgery for pitNET

Identifiers

PMID39466561
PMCPMC11695520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.